Overview
Fraternine is a peptide isolated from the venom of the social wasp Parachartergus fraternus. It is among the least commercially familiar compounds in this catalogue and one of the more interesting, because the single study behind it is methodologically conventional and reports a clean result.
Insect venoms are a recognised source of CNS-active molecules — they evolved for potency and selectivity against nervous systems. The investigators filtered the venom, separated it by HPLC, identified the active fraction by mass spectrometry, and named the novel peptide Fraternine.
They then tested it in the 6-hydroxydopamine (6-OHDA) mouse model of Parkinson's disease, which destroys dopaminergic neurons in the substantia nigra. At 10 µg per animal, Fraternine-treated mice stayed on the rotarod longer than lesioned controls and showed fewer apomorphine-induced rotations — two independent motor readouts. Critically, immunohistochemistry showed the compound also inhibited dopaminergic neuronal loss, meaning the motor benefit was accompanied by preserved neurons rather than merely masking symptoms.
This is one study in one model in one species. It is a starting point for research, not evidence of a treatment.
What the evidence shows
Separated by study type- HumanClinical trials and human studies
- No human studies of any kind.
- AnimalRodent and other animal models
- In a 6-OHDA murine model of parkinsonism, 10 µg/animal Fraternine improved rotarod performance versus the lesioned group, reduced apomorphine-induced rotations, and inhibited dopaminergic neuronal loss in the substantia nigra on immunohistochemistry.
- In vitroCell and tissue studies
- Isolated and identified by HPLC separation and mass spectrometry of wasp venom.
Key studies & findings
1 study- 1
Fraternine at 10 µg/animal improved rotarod retention and reduced apomorphine-induced rotations in 6-OHDA-lesioned mice, and inhibited dopaminergic neuronal loss in the substantia nigra — a motor benefit accompanied by preserved neurons rather than symptomatic masking.
Benefits & effects
3 documentedPrevented dopaminergic neuron loss in the substantia nigra in a 6-OHDA model
Improved rotarod motor performance in lesioned mice
Reduced apomorphine-induced rotational behaviour
Side effects & safety
1 reportedSafety noteResearch compound for laboratory use only. Not approved for human use; no established human safety database outside the trials cited here.
Recorded in the cited literature No safety data of any kind published.
Venom-derived peptides carry general immunogenicity concerns not addressed in the source study
Limitations & open questions
The entire evidence base is a single 2020 study in one animal model. There is no independent replication, no dose-ranging beyond the doses tested, no pharmacokinetics, no toxicology, and no human data. The molecular target is unknown. Venom-derived peptides also carry a general immunogenicity concern that this work did not address.
Pharmacology
Fraternine was isolated from Parachartergus fraternus venom and characterised by mass spectrometry. No PubChem entry was retrievable under this name in this session; molecular formula, weight and full sequence are not stated in the sources located. No pharmacokinetic data exist.
Frequently asked questions
Is Fraternine a Parkinson's treatment?
No. It is a research compound with one published animal study. The 6-OHDA mouse model is a standard screening model, but many compounds that work in it have failed in humans.
What was actually measured?
Two motor tests — time on the rotarod and number of apomorphine-induced rotations — plus immunohistochemistry for tyrosine-hydroxylase-positive neurons in the substantia nigra, which showed the treated animals retained dopaminergic neurons.
Where does Fraternine come from?
The venom of the social wasp Parachartergus fraternus. It was isolated by HPLC separation and identified by mass spectrometry.
Citations
1 sources- 1